Cellular senescence and cell therapy in cardiovascular diseases.

Dehua Chang, Jiaqi Wang, Shuoji Zhu, Yunchao Shentu, Yuanli Wang, Ping Zhu, Minoru Ono

Department of Cardiovascular Surgery, Regenerative Medicine Research on the treatment of Mesenchymal Stem Cells, University of Tokyo Hospital, Tokyo, 113-8654, Japan. [email protected] of Cardiovascular Surgery, Regenerative Medicine Research on the treatment of Mesenchymal Stem Cells, University of Tokyo Hospital, Tokyo, 113-8654, Japan. [email protected]. · pubmed

Paper

Abstract

The issue of population aging presents a significant challenge for many countries, and the related physical health implications have been receiving increasing attention. Senescence impacts several aspects of the cardiovascular system, contributing to diseases such as atherosclerosis, myocardial infarction (MI), pulmonary hypertension, and heart failure (HF). In recent decades, scientists have significantly advanced in understanding the molecular and cellular processes involved in cardiovascular aging, including telomere shortening and damage, oxidative stress, mitochondrial dysfunction, and DNA damage. Molecules such as p53, p21, and p16

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses the role of cellular senescence in cardiovascular diseases and explores potential cell therapy approaches. The relevance lies in its focus on understanding and addressing the underlying mechanisms of aging-related cardiovascular issues, which aligns with longevity research.

Author of this paper? Send a correction.